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Abstract
Introduction IL-17 plays an important role in autoimmunity,
promoting autoimmunity, inflammation and invasion in multiple
sclerosis, rheumatoid arthritis and type I diabetes. The role of IL-
17 in cancer is unclear, however, as there are few studies
examining IL-17 protein expression in cancer. We therefore
examined IL-17 protein expression in human breast cancer and
modelled its potential biological significance in vitro.
Methods Immunohistochemistry was used to determine IL-17
expression in breast cancers. Matrigel invasion assays were
employed to examine the effect of IL-17 on cancer cell invasion
by a panel of breast cancer cell lines. The role of matrix
metalloproteinases (MMPs) was investigated with selective
antagonists and immunoassays for MMP-2, MMP-3, MMP-9 and
tissue inhibitor of MMP.
Results IL-17-expressing cells with macrophage morphology
were identified in the peritumoural area of a proportion of
patients (8/19 patients). Macrophages were confirmed by
CD68 staining on serial sections. With the exception of
occasional lymphocytes, one patient with rare multinucleate
giant cells and one patient with occasional expression of IL-17
in tumour cells, no other IL-17-positive cells were detected.
Addition of IL-17 to cell lines in vitro stimulated marked invasion
of Matrigel. In contrast, IL-17 did not promote the invasion of
MCF7 or T47D cell lines. Invasion was initially thought to be
dependent on MMPs, as evidenced by the broad-spectrum
MMP inhibitor GM6001 and selective antagonists of MMP-2/
MMP-9 and MMP-3. Measurement of MMP-2, MMP-3 and
MMP-9, and tissue inhibitor of MMP 1 secretion, failed to reveal
any changes in expression following IL-17 exposure. In contrast,
TNF promoted secretion of MMPs but IL-17 did not augment
TNF, indicating that IL-17 acts via an independent mechanism.
Conclusions The present study is the first to describe in situ
expression of IL-17 protein in human breast tumours and to
propose a direct association between IL-17 and breast cancer
invasion. The precise effectors of IL-17-dependent invasion
remain to be characterised but could include a range of
proteases such as a disintegrin and metalloproteinase protein or
astacins. Nevertheless, this work identifies a novel potential
mechanism for breast cancer invasion and tumour progression,
the prognostic implication of which is currently under
investigation.
Introduction
In recent years IL-17 has become regarded as a key mediator
at the interface between adaptive and innate immunity. IL-17
plays a critical role in host defence and is important in inflam-
matory and autoimmune diseases, including inflammatory
bowel disease [1], multiple sclerosis [2] and rheumatoid arthri-
tis [3]. Perhaps surprisingly, despite the role of IL-17 in autoim-
munity, relatively little is known about its role in malignancy –
and the data obtained so far are somewhat conflicting. Some
reports show that IL-17 supports tumour growth, probably by
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stimulating angiogenesis of human cervical cancer and murine
fibrosarcoma cells when transfected with IL-17 cDNA [4-6]. In
contrast, other studies suggest that IL-17 promotes T-cell-
mediated tumour rejection [7-9]. One recent study showed
that IL-17 increases the invasive capacity of the JEG-3 human
choriocarcinoma cell line [10], but the mechanisms of action
remain unclear. Importantly, as previous studies have largely
focused on IL-17 mRNA, there is a paucity of studies examin-
ing the expression of IL-17 protein in human malignancy.
Histological inflammation is associated with poor prognosis
and a higher incidence of metastasis in breast cancer [11,12].
Given the patterns of local invasion and the inherent potential
for metastasis associated with the natural history of this dis-
ease, it is believed that local inflammatory cytokines, matrix
metalloproteinases (MMPs) and vascular endothelial cell
growth factor play key roles [13]. Previous studies have
reported that tumour-associated macrophages are a major
component of the lymphoreticular infiltrates of tumours [14],
and high numbers of tumour-associated macrophages are
observed in many tumours including invasive breast cancer
[15]. Furthermore the extent of macrophage infiltration corre-
lates positively with angiogenesis and negatively associates
with prognosis in breast cancer and malignant melanoma
[16,17]. Such macrophages are thought to express higher lev-
els of inflammatory cytokines (for example, TNF, epidermal
growth factor and vascular endothelial growth factor), promot-
ing angiogenesis, tumour growth and invasion [18-21]. The
present study examined the expression of IL-17 in breast can-
cer and identified it as a novel candidate for inflammation-
associated cancer invasion in breast cancer.
Breast cancer is among the four most common human can-
cers [22]. Cancer cells need to invade the surrounding extra-
cellular matrix to gain entry into the lymphatic and vascular
systems for dissemination to distant sites in the body. In this
regard, proteases such as MMPs are key effectors in these
processes. Elevated levels of tumour-derived MMP-9 and
mononuclear inflammatory cell-derived MMP-1/MMP-7/MMP-
9/MMP-11/MMP-13/MMP-14 are significantly associated
with higher rates of distant metastases in breast cancer [23].
Production and activation of MMPs is dependent on various
cytokines, including TNFα and IL-1 secreted by tumour cells
[18,19,21], fibroblasts [24-26] and macrophages [27]. IL-17
stimulates TNFα and IL-1 production by monocytes and mac-
rophages [28], and upregulates MMP-9 production from mac-
rophages [29]. Previous studies found that MMPs, IL-1 and
TNF are regulated by IL-17 in periodontitis [30], and found that
IL-17 receptor deficiency results in impaired expression of IL-
1 and MMP-3/MMP-9/MMP-13 in rheumatoid arthritis [31],
indicating that IL-17 also plays an important role in the regula-
tion of MMPs.
To date there is a paucity of published evidence on IL-17 pro-
tein expression in human malignancy, including descriptions of
its cellular source and its direct effect on breast cancer cells.
In the present study, we identify macrophages as a major cel-
lular source of IL-17 in breast tumours and we show that IL-17
directly promotes breast cancer cell invasion in vitro. The clin-
ical significance of this novel pathway of cancer cell invasion
is currently under investigation; however, IL-17 may represent
an attractive target of potential prognostic or therapeutic
value.
Materials and methods
Reagents
Recombinant human IL-17 and recombinant TNFα were
obtained from R&D Systems (Abingdon, Oxfordshire, UK). A
goat polyclonal anti-human IL-17 antibody and corresponding
neutralising peptide were obtained from Santa Cruz Biotech-
nology (Insight Biotechology, London, UK). A broad-spectrum
MMP inhibitor (GM6001) and selective antagonists of MMPs
(MMP-3 inhibitor II, MMP-2/MMP-9 inhibitor I) were obtained
from Calbiochem (Invitrogen, Paisley, UK). Results of the
immunohistochemistry and Matrigel analyses were determined
using a Nikon microscope (Eclipse E600, Fujitsu Ten, Kobe,
Japan).
Specimens and immunohistochemistry
To determine whether IL-17-producing cells were present in
breast cancer, archival paraffin-embedded sections of 19 pri-
mary invasive breast tumours (15 Grade III and four Grade II)
were obtained from the Department of Histopathology, City
Hospital, Nottingham, UK. The density of the inflammatory infil-
trate was examined in those sections, and was scored using a
semiquantitative system that recorded a value of 0 for lack of
inflammation, 1+ for mild inflammation and 2+ for marked
inflammation. Figure 1c shows an example of 2+ inflammation.
Eleven specimens showed no inflammation, four specimens
showed mild (1+) inflammation, and four specimens showed
dense (2+) inflammation (Table 1). Two independent his-
topathologists (RAAM and AHSL) examined the staining pat-
tern in a blinded matter. Ethical approval was obtained for the
analysis, from the Nottingham Local Research Ethics Commit-
tee (REC C2020313).
The staining of IL-17 antibody on paraffin-embedded sections
was first optimised on tonsil sections (enlarged hyperplastic
tonsil from tonsillectomy). Briefly, 4 μm sections were depar-
affinised in xylene and then rehydrated in a graded sequence
of ethanol solutions. For antigen retrieval, sections were pre-
treated in ethylenediamine tetraacetic acid buffer (p H9) in a
microwave (800 W, 10 min high power, 10 min low power).
After cooling, nonspecific binding was blocked with diluted
serum (goat IgG ABC kit; Vectastain (Vector Laboratories,
Peterborough, Cambridgeshire, UK) followed by incubation
with goat polyclonal anti-human IL-17 antibody (diluted 1:100
in blocking serum) at room temperature in a humidified cham-
ber. As a negative control, sections were incubated with nor-
mal goat IgG or the primary antibody was preincubated with aAvailable online http://breast-cancer-research.com/content/10/6/R95
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neutralising specific peptide that completely abrogated stain-
ing (Figure 1). After incubation with the primary antibody, sec-
tions were washed with PBS and subsequently treated using
the goat IgG ABC kit according to the manufacturer's proto-
col. Peroxidase activity was visualised using the 3,3'-diami-
nobenzidine kit (Vector Laboratories), and sections were
counterstained with haemotoxylin. Staining was examined by
specialist consultant breast histopathologists from the Depart-
ment of Histopathology, City Hospital, Nottingham, UK.
Cell lines and culture
A panel of breast cancer cell lines was used for in vitro studies.
The adenocarcinoma cell line MCF-7 and the ductal carci-
noma cell line MDA-MB435 were cultured in RPMI-1640
(Sigma-Aldrich, Poole, Dorset, UK) plus 10% FCS (Sigma).
The T47D ductal carcinoma cell line was cultured in RPMI-
1640, 10% FCS and 0.1 μM 2-mercaptoethanol (Sigma),
whilst the adenocarcinoma cell line MDA-MB231 was cul-
tured in MEM (Sigma), 10% FCS, L-glutamine (Sigma) and
nonessential amino acid solution (Sigma). All cells lines con-
sistently screened negative for mycoplasma.
Matrigel invasion assay
Six-well Matrigel Invasion Chambers (BD Biosciences, Oxford,
UK) were used to study the invasiveness of tumour cell lines.
Depending on the cell line used, RPMI-1640 or MEM supple-
mented with 10% FCS was added to the lower wells of the
chamber. Cells were resuspended at 1.25 × 105/ml (total 2
ml) in appropriate serum-free media supplemented with 0.1%
BSA (Sigma), and were added to the upper compartment of
the chamber. After settling, cells were treated with IL-17,
TNFα or IL-17 plus MMP-3 inhibitor II/MMP-2/MMP-9 inhibitor
I (1 μM) or GM6001 (100 μM). Unstimulated control inserts
were always included. Plates were incubated for 22 hours at
37°C, following which noninvading cells were removed from
the upper surface of the transwell membrane using a cotton
swab. Transwell filters were then fixed in 100% methanol for 2
minutes and then stained in Toluidine Blue solution (Sigma) for
2 minutes before washing in water.
Inserts were excised and mounted onto microscope slides.
Images of cells from three representative fields were captured
digitally and the number of cells present on the transwell was
counted. Results are presented as the average of triplicate
determinations and each experimental condition was repeated
on at least three separate occasions.
Assay for IL-17, TNFα, MMPs and tissue inhibitor of 
matrix metalloproteinase 1
TNFα was measured using the Bio-Rad Luminex system
(Hemel Hempstead Hertfordshire, UK). Culture supernatants
were incubated with TNFα antibody bead concentrate, fol-
lowed by biotinylated detector and streptavidin-RPE using the
Biosource extracellular protein buffer kit (London, UK). Stand-
ard curve and interpolated results were calculated with Bio-
plex manager 3.0 software (Bio-Rad Laboratories, Hercules,
CA, USA).
Figure 1
Immunohistochemical staining of IL-17-positive macrophages in breast  cancer Immunohistochemical staining of IL-17-positive macrophages in 
breast cancer. (a) Tonsil section stained with IL-17 showing IL-17-
positive cells: the shape and distribution of these cells indicate they are 
the macrophages within the germinal centre of the lymphoid follicles 
(magnification ×200). Staining of IL-17-positive cells in sections from 
breast cancer: (b) IL-17-positive cells located in the peritumoural areas 
(magnification ×200); (c) IL-17-positive macrophages characterised by 
having an oval or irregular shape, a kidney-shaped nucleus and a prom-
inent nucleolus located at the nuclear membrane (arrows and inset) 
(magnification ×400) – this is a typical example of the level of inflamma-
tion scored as 2+; and (d) peritumoural area with dense inflammatory 
infiltrate showing one giant cell – a large-sized cell with multiple nuclei 
(arrow & inset) (magnification ×400). In all positive cells, staining was 
found to be only cytoplasmic and the nuclei are completely negative. 
(e), (f), (g), (h) Examples of IL-17 and CD68 staining in consecutive 
sections of breast cancer. Because it was not possible to satisfactorily 
stain IL-17 and CD68 on the same section, we stained consecutive 
sections for each antigen. As can be seen, whilst the tumour (T) is neg-
ative, the IL-17-positive cells in the surrounding stroma were found in 
similar areas to the CD68+ macrophage (red arrow).Breast Cancer Research    Vol 10 No 6    Zhu et al.
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MMP-2, MMP-3 and MMP-9 were assayed in the cell-free
supernatants of breast cancer cell lines using the Luminex
assay as per manufacturer's instructions (R&D Systems). Lev-
els of the tissue inhibitor of matrix metalloproteinase (TIMP)-1
and TIMP-2 tissue inhibitors were assayed by ELISA accord-
ing to the manufacturer's instructions (R&D Systems).
Secretion of IL-17A was measured in standardised superna-
tants collected from the panel of breast cancer cell lines. Cells
were seeded in 24-well plates (105/ml) and were cultured for
48 hours. Cell-free supernatants were harvested, and the
secreted IL-17A was determined using a modified DuoSet
ELISA assay (R&D Systems). This ELISA does not react with
IL-17B, IL-17C, IL-17D, IL-17E or IL-17F and has a sensitivity
of 15 pg/ml for IL-17A.
Statistical analysis
The statistical analysis on breast cancer cell invasion was per-
formed using a Student t test provided in SPSS software (Chi-
cago, Illinois, USA).
Results
Expression of IL-17 in breast tumours
To date there have been no published descriptions of IL-17
protein expression and localisation in breast cancer. We there-
fore undertook to stain a series of breast tumours for IL-17
using a modified immunohistochemistry technique. Initial stain-
ing of control tonsil sections showed scattered IL-17-positive
cells (Figure 1a) and this staining was completely blocked with
a specific neutralising peptide, thus confirming the specificity
of the antibody (data not shown). Immunohistochemical stain-
ing was examined by a consultant histopathologist, and the
morphology and distribution of these cells indicated they were
macrophages located within the germinal centre of the lym-
phoid follicles and in the interfollicular areas.
In eight out of the 19 stained breast tumours (Table 1) we
observed the presence of IL-17 strongly positive cells within
the scattered tumour-associated inflammatory infiltrate. These
IL-17-positive cells were located mainly in the peritumoural
areas and associated with pronounced mononuclear cell infil-
tration (Figure 1b). The majority of IL-17-expressing cells
(>98%) exhibited classical macrophage morphological char-
acteristics, including an oval or kidney-shaped medium-sized
nucleus, a prominent nucleolus located at the nuclear mem-
brane, fine chromatin and abundant cytoplasm (Figure 1c).
Positive staining was restricted to the cytoplasm and no
nuclear staining was observed. None of the tumour cells
stained for IL-17 expression; however, a small number of lym-
phocytes and an occasional plasma cell showed cytoplasmic
staining. In one patient's tumour, occasional multinucleate
giant cells also showed cytoplasmic staining (Figure 1d).
It was not possible to obtain satisfactory dual staining for intra-
cellular IL-17 and the macrophage marker CD68 on archival
material. To further demonstrate the origin of the IL-17-positive
cells we stained consecutive sections for the macrophage
marker CD68. Cells that were positive for CD68 occurred in
the same area of the tumour material and, as expected, dis-
played similar morphological characteristics as IL-17-positive
cells (Figure 1e to 1g). Staining of IL-17 was observed in a
fraction of the tumour cells from only one patient (Figure 2d).
Whilst there were occasional intratumoural macrophages (Fig-
ure 2e), these were not in sufficient abundance to account for
IL-17 staining in tumour cells per se. The specificity of IL-17
staining was confirmed by the preincubation of antibody with
the specific neutralising peptide, which resulted in almost
complete ablation of signal (Figure 2c,f).
To further explore this observation, we analysed the secretion
of IL-17 from a panel of breast cancer cell lines including the
MDA-MB435 cell line – which, although frequently described
as of mammary adenocarcinoma origin, may actually originate
from metastatic melanoma. None of the cell lines studied con-
stitutively secreted detectable levels of IL-17 (data not shown).
IL-17 drives invasiveness of breast cancer cell lines in 
vitro
Because of the observed peritumoural pattern of IL-17 stain-
ing in breast cancer and the known contribution of macro-
phages to tumour invasion [27,32], we examined the influence
of IL-17 on the invasive capacity of a panel of breast cancer
cell lines. Addition of IL-17 to the MDA-MB231 and MDA-
MB435 cell lines promoted marked and significant invasion of
Matrigel (Figures 3 and Figure 4). Breast cancer invasion has
previously been shown to be strongly promoted by TNFα, and
in our experiments IL-17-dependent invasion was of similar
magnitude to that achieved following stimulation with TNFα. In
Table 1
Summary of the immunohistochemical staining of IL-17 in breast cancer
Grade (number of patients) Inflammatory infiltrate IL-17-positive cells Lymph-node-positive Lymph vascular invasion
Grade III (n = 15) 4+, 3++ 8 7 (4) 7 (5)
Grade II (n = 4) 1++ 0 2 2
Total (n = 19) 8 8 9 (4) 9 (5)
Paraffin-embedded sections from 19 patients were stained and analysed. +, mild inflammation; ++, dense inflammation. Data in parentheses are 
IL-17-positive cells.Available online http://breast-cancer-research.com/content/10/6/R95
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contrast, the MCF-7 and T47D cell lines, classically regarded
as noninvasive, had no intrinsic invasive capacity, and did not
invade Matrigel in response to either TNFα or IL-17 (Figures 3
and 4).
IL-17-dependent invasion of breast cancer cell lines is 
inhibited by selective-antagonists of MMP-2, MMP-3 and 
MMP-9
Invasion of Matrigel is thought to require the presence and
activation of MMPs [27]. We therefore examined the role of
MMPs in IL-17-dependent invasion of Matrigel using a panel of
selective MMP antagonists. Addition of the pan-MMP inhibitor
GM6001 (inhibitor of MMP-1, MMP-2, MMP-3, MMP-8 and
MMP-9) caused a significant inhibition of IL-17-dependent
invasion (P < 0.001). Furthermore, selective antagonists for
MMP-2/MMP-9 or MMP-3 also suppressed the stimulatory
effect of IL-17 on breast cancer invasion, although to a lesser
extent than GM6001 (Figure 4). Although significantly inhib-
ited, the MMP-3 selective antagonist was the least effective at
reducing the invasiveness of the MDA-MB231 and MDA-
MB435 cell lines.
To further address a possible role for MMPs in IL-17-depend-
ent invasiveness of breast cancer cell lines, we assayed the
supernatants from IL-17-treated and control MDA-MB231 and
MDA-MB453 cells for the presence of MMP-2, MMP-3, MMP-
9 and TIMP-1. Control cells produced low levels of MMP-3
and MMP-9 (Figure 5a). Following treatment with TNFα, these
levels were markedly increased. Despite the addition of up to
400 ng/ml recombinant IL-17, however, no increase in MMP-
3 or MMP-9 was observed. The levels of MMP-2 released by
breast cell lines (IL-17-treated or otherwise) was below the
minimum sensitivity of the assay (data not shown). We meas-
ured the presence of the tissue inhibitors TIMP-1/TIMP-2 on
the basis that decreased TIMP levels permit enhanced MMP
function to be manifested. The level of soluble TIMPs, how-
ever, remained unchanged by the addition of IL-17 or TNFα
(data not shown).
IL-17 does not induce TNFα secretion from breast cancer 
cells
Several studies have highlighted an association between IL-
17 expression and TNFα production, and in some systems IL-
17 directly stimulates release of TNFα [28,30]. We therefore
investigated the possibility that IL-17 exerted its effect on
breast cancer cells by inducing TNFα secretion, which in turn
could drive MMP-dependent tumour invasion. The breast
tumour cell lines studied constitutively secreted low levels of
TNFα, and this was not increased by the addition of 200 ng/
ml IL-17 (Figure 5b). Furthermore, the addition of recombinant
IL-17 did not increase the secretion of TNFα, irrespective of
the dose of IL-17 added (data not shown). The levels of TNFα
Figure 2
Expression of IL-17 in breast cancer Expression of IL-17 in breast cancer. (a) to (c), (d) to (f) Consecutive sections from two patients stained for (a), (d) IL-17 and (b), (e) the CD68 
macrophage marker. (c), (f) A further consecutive section showing the staining obtained when the IL-17-specific antibody was preincubated with a 
specific neutralising peptide. (d) Of interest, in one out of 19 patients studied there were occasional areas of tumour (T) that stained specifically with 
the anti-IL-17 antibody.Breast Cancer Research    Vol 10 No 6    Zhu et al.
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secreted following IL-17 treatment was in fact lower than con-
trol cells. One should bear in mind that these levels are very
low, however, and variation at these levels is unlikely to be bio-
logically significant. In this regard, using the TNFα ELISA we
assayed the recombinant TNFα added as a positive control for
the invasion assays (expected 40 ng/ml) and obtained a value
of 17,205 ± 1,020 pg/ml. Therefore IL-17 does not appear to
act by inducing TNFα production from breast tumour cells,
and as such may represent an additional pathway involved in
the spread of breast cancer.
Discussion
The recent identification of a new subtype of T-helper cells
(Th17) has prompted renewed interest in IL-17 biology. Our
current understanding of IL-17 is that it plays an important role
in inflammation, and is critical in host defence against infec-
tious disease and in allergy and autoimmunity [33-35]. Most
recently Hsu and colleagues reported that IL-17 from Th17
cells promotes the development of germinal centre-derived
autoantibodies in a mouse model disease setting, due to the
stimulatory effect on B-cell development [36]. Our data from
Figure 3
IL-17 promotes the invasiveness of breast cancer cell lines IL-17 promotes the invasiveness of breast cancer cell lines. Representative micrographs (magnification ×200) of Transwell filters following the 
invasion of the four indicated tumour cell lines either resting, treated with IL-17 (100 ng/ml), treated with TNFα (40 ng/ml) or in the additional pres-
ence of a pan-matrix metalloproteinase inhibitor GM6001 for 22 hours. Because of the absence of invasion for the MCF7 and T47D cell lines, the 
micrographs in the additional presence of matrix metalloproteinase inhibitor are not included.Available online http://breast-cancer-research.com/content/10/6/R95
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control tonsil sections may also provide support for the
concept that IL-17 plays an important role in B-cell develop-
ment. In contrast to the murine model, however, our studies
revealed that IL-17 expression was largely restricted to macro-
phages rather than T cells. It is worth emphasising that most
studies to date are based on murine models, with a strong
focus on Th17 cells. Although IL-17 is also expressed by epi-
thelial cells, synovial cells and macrophages [1,37,38], the
mechanisms driving IL-17 expression in these cell types
remain unclear.
Pronounced leukocyte infiltration is considered a poor prog-
nostic factor in breast cancer and those patients with tumoural
leukocyte infiltration have a decreased 5-year survival [11,12].
Whilst the precise mechanisms for this remain unknown, there
is a growing body of evidence to support the hypothesis that
inflammation assists in the invasion of tumour cells [18-21].
This assistance involves the upregulation of IL-1, IL-6, IL-8,
TNFα and MMPs that promote surrounding tissue destruction,
leading to tumour invasion and ultimately metastasis. To our
surprise, in our study there was little evidence of T cells
expressing IL-17 in the tumours of breast cancer patients. In
fact the majority of IL-17-positive cells (>98%) were macro-
phages, as defined by cytological criteria and CD68 staining.
When we examined the stained tonsil tissue, which enlarges
and becomes hyperplastic in response to infectious or allergic
stimuli, we found abundant IL-17-positive cells located mainly
in the germinal centres of the lymphoid follicles and in interfol-
licular areas. As in the breast tumours, the oval or irregular
shape and the kidney-shaped nucleus that has a prominent
Figure 4
IL-17 promotes invasion of Matrigel IL-17 promotes invasion of Matrigel. (a) IL-17 stimulates breast cancer cell invasion and is suppressed by selective matrix metalloproteinase 
(MMP) antagonists as indicated. Breast tumour cell lines were incubated in serum-free conditions in the absence or presence of IL-17 (200 ng/ml) 
± MMP antagonists on the upper chamber of a Matrigel-coated transwell for 22 hours at 37°C. The Matrigel layer was removed and the cells on the 
transwell were stained prior to mounting, imaging and enumeration. The number of cells migrated onto the transwell per field (magnification ×100) 
were counted, three representative fields for each condition were enumerated, and each condition was repeated at least three times in separate 
experiments. Statistical significance is indicated where appropriate. ns, not significant. (b) Comparison of the proinvasive effect of IL-17 (200 ng/ml, 
white bar) versus TNFα (40 ng/ml, grey bar) versus untreated cells (black bar) on a panel of four breast cancer cell lines. Invasion assays were con-
ducted as described above. Data represents the mean ± standard deviation of triplicate determinations and is representative of five independent 
experiments. Statistical significance is indicated.Breast Cancer Research    Vol 10 No 6    Zhu et al.
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nucleolus located at the nuclear membrane are the histopatho-
logical features that together with CD68 positivity enabled us
to identify them as macrophages. Our finding together with the
study of Fujino and colleagues – who reported IL-17-positive
cells from inflammatory bowel disease, and found that most of
the IL-17-positive cells are CD6-positive with a small number
of CD3-positive cells [1] – indicates that IL-17-positive macro-
phages exist in some inflammatory conditions.
In addition to IL-17A, the subject of the current study, macro-
phages are also reported to express IL-17F, which is under-
stood to suppress angiogenesis [39]. We propose to
determine the relative expression of IL-17A versus IL-17F mol-
ecules in future studies. It has previously been shown that
multinucleate giant cells express high levels of chemokines
and MMP-9, and play an important role in inflammatory
response [40,41]. The factors controlling multinucleate giant
cell formation in cancer remain poorly understood, but a role
for inflammatory cytokines such as IL-17 should not be
discounted.
Whilst current theory supports the concept of inflammation
promoting tumour progression, this is by no means the only
possibility – and in breast cancer a body of evidence exists to
oppose this. The significance of the inflammatory infiltrate in
invasive carcinoma of the breast may represent an immune
response to the tumour or may have protumour effects. Some
large studies using multivariate analysis including grade sug-
Figure 5
Effect of IL-17 on MMP and TNF expression Effect of IL-17 on MMP and TNF expression. (a) IL-17 does not affect the secretion of matrix metalloproteinase (MMP)-2, MMP-3, MMP-9 or tis-
sue inhibitor of matrix metalloproteinase (TIMP). The supernatants of control and treated (IL-17 or TNFα) tumour cell lines were assayed for the pres-
ence of MMP-2, MMP-3, MMP-9 and TIMP-1 and TIMP-2 by Luminex immunoassay or ELISA. The invasive breast cancer cell lines MDA-MB231 and 
MDA-MBA435 were seeded into 24-well plates (1 × 105/well) and rested overnight. Cells were treated with IL-17 (200 ng/ml) or TNFα (40 ng/ml) 
for 24 hours and the supernatants were harvested for assay. Results are representative of two independent assays and show the mean ± standard 
deviation of triplicate determinations for one of two experiments (*P < 0.01). The levels of MMP-2 were unaffected by any treatment, and the levels 
of TIMP inhibitors remained unchanged (data not shown). (b) IL-17 acts independently of TNFα. A panel of breast cancer cell lines were seeded into 
24-well plates (1 × 105/well) and rested overnight. Cells were left untreated (grey bar) or were treated with 200 ng/ml IL-17 (black bar) for 24 hours 
and the supernatants were harvested for TNFα ELISA. Results are representative of two independent assays and show the mean ± standard devia-
tion of triplicate determinations for one of two experiments (*P < 0.01). The concentration of recombinant added TNFα (expected 40 ng/ml) required 
to stimulate migration was actually found to correspond to 17,205 ± 1,020 pg/ml in this assay.Available online http://breast-cancer-research.com/content/10/6/R95
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gested that inflammation is associated with better prognosis
[42,43]. Nevertheless, we show that IL-17 promotes tumour
invasion, and IL-17-positive macrophages were only identified
patients with grade III disease. This may indicate a protumour
effect of inflammation.
Co-culture of macrophages with breast cancer cells results in
a marked increase in tumour cell invasion, which is associated
with upregulation of MMP-2 and MMP-9 [44]. This invasion
was attenuated by anti-TNFα antibodies and demonstrates
that cancer cells utilise surrounding cells to facilitate invasion
of the surrounding extracellular matrix. This represents a key
mechanism by which tumour-infiltrating macrophages play an
important role in cancer progression. The signals governing IL-
17 expression by macrophages remain to be identified. Using
tumour–macrophage co-culture systems, we are currently
investigating the regulation of IL-17 expression by macro-
phage. Furthermore, we are examining the control of macro-
phage IL-17 expression by factors known to regulate the
evolution of Th17 responses including IL-1, IL-6, IL-21 and
transforming growth factor beta.
It should be noted that although MDA-MB435 is currently
used in many studies as a breast cancer cell line, there is
debate over its origin as one study suggests that this cell line
is of melanoma origin [45]. In this regard we are currently
expanding our work to include malignant melanoma, colorectal
carcinoma, pancreatic carcinoma and ovarian carcinoma. We
have begun staining a large series of whole sections from con-
secutively recruited breast cancer patients in Nottingham, UK.
All of these patients have full follow-up data, so upon comple-
tion of the staining it will be possible to examine the correlation
of IL-17 expression with patient parameters including lym-
phovascular invasion, stage, grade, 5-year survival, time to pro-
gression, and so forth [46].
IL-17-dependent invasion of breast tumours was blocked by a
range of selective MMP antagonists for MMP-2, MMP-3 and
MMP-9 as well as a broad-spectrum MMP antagonist. As we
were unable to measure changes in MMP-2, MMP-3, MMP-9
or TIMPs following IL-17 exposure, however, we are unable to
confirm that IL-17 acts through MMPs. In contrast, tumour
cells secreted abundant MMP-3 and MMP-9 following TNF
treatment, suggesting the use of nonredundant pathways by
IL-17 and TNF. Whilst the exact mechanism of IL-17-depend-
ent tumour cell invasion remains unknown, the antagonists we
employed do not exclusively inhibit MMPs and may act on
other classes of protease – including disintegrin and metallo-
proteinase proteins (for example, ADAM12) and astacins such
as meprin, which displays activity similar to the gelatinases,
MMP-2 and MMP-9 [47]. This will be investigated by gene
expression studies with the use of more specific inhibitors and
will be confirmed with siRNA. One possibility is that IL-17 acts
through TNFα, but we saw no evidence of increased TNFα
release from IL-17-treated tumour cells. There are several
other candidates that may mediate the effect of IL-17. It is
already known that IL-17 stimulates tumour cells, epithelial
cells and fibroblast cells to produce IL-8 [48]. In turn, IL-8 pro-
motes granulocyte recruitment and stimulates expression
MMPs, remodelling the extracellular matrix and promoting can-
cer cell invasion [49]. In this regard we are presently investi-
gating the regulation of factors such as IL-6, IL-8 and IL-22 in
breast cancer cells treated with IL-17. Furthermore, we are
presently investigating the expression of the two key IL-17
receptor chains on breast cancer cells, RA and RC, which het-
erodimerise to mediate signalling following binding of IL-17A
and IL-17F.
Conclusion
In summary, the present article is the first description of IL-17
protein expression in the context of human tumours and we
have shown that expression appears largely restricted to mac-
rophages. Most importantly, in companion experiments IL-17
directly induced breast cancer cell invasion independently of
TNFα. Whilst invasiveness was inhibited by MMP selective
antagonists, there were no measurable changes in levels of
MMP-2, MMP-3 or MMP-9, raising the possibility of other
classes of protease being involved. As such we describe a
novel potential mechanism for breast cancer invasion and
tumour progression. A detailed understanding of the IL-17-
invasion axis may be of future prognostic and therapeutic
value.
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